DNA Methylation Biomarker Panels for Early Cervical Cancer Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current screening methods for cervical cancer lack robust, highly accurate, and sensitive biomarkers for early detection and risk prediction, particularly in asymptomatic or precancerous stages, posing challenges in managing women with cervical intraepithelial neoplasia (CIN) and identifying those at risk of progressing to invasive cervical cancer.
Innovation Solution
Development of DNA methylation biomarkers, specifically CGID biomarkers, identified through the 'analysis of progressive DNA methylation alterations (APDMA) method, which utilize genome-wide methylation profiles and next-generation sequencing to detect cervical cancer with high sensitivity and specificity, even in early stages, using a panel of CGIDs that are uniformly methylated in cancer and unmethylated in normal tissues.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current screening methods (Pap smears, liquid based cytology, HPV testing) are used, then screening can be performed, but sensitivity and specificity for early detection of cervical cancer are insufficient
Solution Approach 1:
The invention segments the detection process by focusing on specific CpG sites within genes rather than performing general cytological examination or broad HPV testing. The panel targets specific methylated CpG sites (e.g., in genes like RARβ, CDH1, DAPK1) to achieve more precise and reliable detection of cervical cancer at early stages.
Solution Approach 2:
The invention changes the detection parameter from cellular morphology (Pap smear), protein expression (HPV testing) to DNA methylation status at specific CpG sites. This parameter change enables detection of epigenetic modifications that occur during carcinogenesis, improving both sensitivity and specificity for early detection.
2Reliability
If aggressive ablative or excisional treatment is applied to women with CIN pathologies, then lesion removal is achieved, but immediate complications and increased risk of miscarriage or premature delivery occur
Solution Approach 1:
The invention performs preliminary detection of cervical cancer through DNA methylation biomarker analysis before initiating treatment. By identifying women with early-stage cancer versus those with benign CIN lesions, the system enables selective management strategies that avoid unnecessary aggressive treatment in low-risk patients, thereby preventing pregnancy complications while maintaining effective cancer treatment.
Solution Approach 2:
The invention applies different management approaches based on the specific methylation profile detected. Women with methylation patterns indicative of early cancer receive appropriate cancer treatment, while those with benign patterns avoid aggressive intervention, thus tailoring treatment to the actual pathological state and minimizing harmful effects on pregnancy outcomes.
3Measurement precision
If a panel of multiple DNA methylation biomarkers is used, then detection sensitivity and specificity improve to >95%, but device complexity and cost increase
Solution Approach 1:
The invention combines multiple DNA methylation biomarker detections into a single integrated panel assay. By simultaneously analyzing methylation status across multiple CpG sites in different genes, the system achieves synergistic improvement in sensitivity and specificity (>95%) while streamlining the overall diagnostic process into one comprehensive test rather than multiple separate assays.
Data Source
AI summary
The present invention discloses an in vitro method for obtaining DNA methylation biomarkers as exquisite DNA methylation positions in the human genome (i.e., CGIDs) that predict cervical cancer especially at as yet inaccessible early stages by examining progression of “categorical” DNA methylation alterations in three stages of premalignant lesions (cervical intraepithelial neoplasia (CIN)), progressing from CIN1 to CIN3. The present invention discloses combinations of CGIDs for detecting with high specificity and sensitivity cervical cancer by measuring their DNA methylation status and deriving a “methylation score”, which is useful as a biomarker for cervical cancer. Also disclosed are kits for predicting cervical cancer using such CGIDs using multiplexed next generation sequencing methylation assays, pyrosequencing assays and methylation specific PCR. The DNA methylation markers (CGIDs) described in the present invention are useful for cervical screening and early detection of cervical cancer by any person skilled in the art to detect cervical cancer.